Ask what Selank is and you'll get a tidy answer: a Russian anti-anxiety peptide, as effective as a benzodiazepine but without the sedation, tolerance or withdrawal. It's a claim repeated so often across peptide forums and vendor pages that it has hardened into fact. But when you go looking at the Selank research behind it, the entire human case rests on three small Russian trials — and not one of them included a placebo arm. That single design choice is the reason "as good as a benzo" is a sentence the data cannot support, and it's worth understanding before you read another word about Selank in Australia.

For background on the molecule itself — a heptapeptide built from the immune fragment tuftsin with a Pro-Gly-Pro tail bolted on for stability — see our Selank profile.

What Is Selank, and What Do the Human Trials Actually Show?

Selank is registered in Russia for mild anxiety disorders. Elsewhere, including Australia, it has never been through an approval process. The published human evidence is three studies, all Russian, the newest from 2015.

2008: Selank vs medazepam

The foundational trial, by Zozulia, Neznamov and colleagues in Zhurnal Nevrologii i Psikhiatrii, randomised 62 patients with generalised anxiety disorder and neurasthenia — 30 to Selank, 32 to the benzodiazepine medazepam. Outcomes were Hamilton, Zung and Clinical Global Impression scales, plus serum enkephalin-degrading activity. The authors described Selank's anxiolytic effect as comparable to medazepam, with an additional anti-asthenic component and a rise in leu-enkephalin half-life that tracked with anxiety reduction.

Note what isn't there: the English-language abstract reports no scale deltas, no p-values and no responder rates. The comparison is qualitative.

2014: Selank vs phenazepam

Medvedev and colleagues ran a comparison of anxiolytic effect and tolerability between Selank and phenazepam, another Russian benzodiazepine, in patients with anxiety disorders. Again the comparator was an active drug, not placebo, and again the accessible English record is descriptive rather than numerical.

2015: Selank added to phenazepam

The newest human study is an adjunct design, not a head-to-head: 30 patients on phenazepam monotherapy versus 40 on phenazepam plus Selank, across anxiety-phobic, hypochondriacal and somatoform disorders. The reported finding was that adding Selank reduced phenazepam's unwanted effects — attention and memory impairment, asthenia, sedation, longer sleep, sexual disturbance, emotional blunting, orthostatism — both during treatment and after the benzodiazepine was withdrawn.

That's an interesting hypothesis. It is also 70 people, in one centre, unreplicated for over a decade.

Why "No Placebo Arm" Matters More in Anxiety Than Almost Anywhere Else

An active-comparator trial without a placebo arm can tell you whether two drugs look similar. It cannot tell you whether either one beat doing nothing. In most therapeutic areas that's a nuisance. In anxiety it's close to fatal, because the placebo response is enormous.

A three-level meta-analysis covering 366 outcome measures from 135 studies in anxiety, obsessive-compulsive and stress disorders (n = 12,583) found an average response rate in the placebo arms of 37%, with 24% reaching remission. In other words, more than a third of people improve on an inert intervention delivered with clinical attention, structured follow-up and expectation.

Put a Selank arm and a benzodiazepine arm side by side in a small unblinded study, and a 37%-style background response would lift both. Both look like they worked. Neither has been shown to work. This is the specific, unglamorous reason regulators outside Russia have not acted on the Selank file — not suppression, not obscurity, just an evidence package that wasn't built to answer the question.

The same logic applies to the tolerability claim, which is the more interesting one. "Fewer side effects than phenazepam" is an easier bar than "better than placebo," and it's plausible on mechanism: Selank's GABAergic activity is reported not to run through the benzodiazepine binding site, so the sedation-amnesia-myorelaxation package that comes bundled with benzodiazepine receptor occupancy needn't follow. Plausible is not proven.

The Newest Selank Research Is Still Rodent Work

If you want the current frontier, it isn't in people. A 2025 paper in Neurochemical Journal dosed male BALB/c mice — a strain bred for high baseline anxiety — with diazepam or mezapam alone versus in combination with Selank, and reported more entries into and time spent in the open arms of an elevated plus maze in the combination groups (Springer). An earlier 2017 rat study under chronic mild stress reported the same direction of effect with diazepam.

So the "Selank makes benzodiazepines work better with fewer costs" idea now has: one 70-person unblinded human trial from 2015, and rodent maze data from 2017 and 2025. That is a coherent research programme in its early stage. It is not a clinical conclusion, and elevated plus maze behaviour in an inbred mouse is not human anxiety.

Is Selank Legal in Australia? The Regulatory Position

Selank sits in the same awkward category as most of the compounds in our peptides library. It is unscheduled in the Poisons Standard — it isn't individually named in the SUSMP — but that is not the same as approved. Selank is an unapproved therapeutic good in Australia: it is not on the ARTG, so it cannot be lawfully supplied, advertised or imported for therapeutic use through ordinary channels. Access, where it exists at all, runs through prescriber-based pathways with the usual conditions attached.

The TGA has been increasingly direct about this. Its compliance work on unapproved peptide products explicitly targets unlawful importation, manufacture, advertising and supply, with infringement notices, seizures, import interventions and civil or criminal penalties among the responses. "Not scheduled" has never meant "freely sellable," and the regulator has closed the gap between those two readings fairly aggressively.

One point of genuine clarity for athletes: Selank is not on the WADA 2026 Prohibited List. That is a doping-control fact only. It says nothing about safety, efficacy or legality of supply in Australia.

What Would Actually Settle the Question

A modern Selank trial isn't technically difficult. It would need a placebo arm, double blinding, a pre-registered primary endpoint (HAM-A change at a fixed week), a sample sized for that endpoint rather than for convenience, and a Western population to test whether a 2008 Russian result generalises. None of that has been done in the 11 years since the last human study was published.

Until it is, the honest summary is short: Selank has been used in Russia for two decades with an apparently benign tolerability record, three small trials suggest it does something in the same neighbourhood as a benzodiazepine, and the trial designs used cannot separate that something from the 37% of people who improve on placebo.

Want the next piece of Selank evidence when it lands, without the marketing gloss? Join the free updates list.

FAQ

Is Selank legal in Australia?

Selank is unscheduled in the Poisons Standard, but it is an unapproved therapeutic good — it's not on the ARTG, so it can't lawfully be supplied, advertised or imported for therapeutic use through normal channels. Unscheduled does not mean approved or freely sellable.

Is Selank as effective as a benzodiazepine?

That claim comes from small Russian trials that compared Selank against medazepam and phenazepam without a placebo arm. Those designs can show two drugs look similar, but they cannot show either one beat placebo — a serious gap given 37% of people respond to placebo in anxiety trials.

How many human trials of Selank are there?

Three, all Russian, with the newest published in 2015. The largest reported participant counts are 62 (2008, Selank vs medazepam) and 70 (2015, Selank added to phenazepam). None was placebo-controlled and none has been replicated outside Russia.

Is Selank banned by WADA?

No. Selank does not appear on the WADA 2026 Prohibited List. That is a doping-control statement only and says nothing about its legal supply status or safety in Australia.

Sources

This article is independent information, not medical advice. Selank is not approved by the TGA and is an unapproved therapeutic good in Australia; discuss any health decision with a qualified Australian health professional.